• REIT Deals are Still Closing Despite COVID-19

    Despite COVID-19 taking a hit on REIT stocks and earnings, especially in the senior care industry, some buyers managed to close deals in May, primarily for medical office buildings. This might come as a surprise since physician practices are getting hit especially hard by COVID-19, so these deals may have been in the works before the pandemic... Read More »
  • Health Care M&A Deals, May 22, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. This week’s top deals include... Read More »
  • WELL Health Boosts Digital Health Portfolio

    WELL Health Technologies Corp. (TSX.V: WELL) has added another digital health firm to its growing portfolio. This week, the Canadian company announced it is acquiring Indivica, Inc. for $4.47 million (CA$6.2 million), consisting of CA$3.41 million in cash upon closing; CA$1.55 million in WELL common shares and a time-based earn-out of CA$1.24... Read More »
  • NaviHealth Changes Owners – Again

    The merry-go-round of owners may finally be slowing for naviHealth, a digital healthcare company that helps health systems and insurers manage post-acute care bundled payments. In its third change of command, naviHealth is now part of OptumHealth, which is part of the Optum division of UnitedHealth (NYSE: UNH). It now manages post-acute services... Read More »
  • Omada Health Adds Physera

    Omada Health, a digital health coaching company based in San Francisco, didn’t have to go far to find a perfect target. On May 19, the company announced its acquisition of Physera, Inc., a digital physical therapy provider also based in San Francisco. In conjunction with the acquisition, Omada raised an additional round of growth capital... Read More »
CROs Are Still Trending as Q4 Rolls On

CROs Are Still Trending as Q4 Rolls On

In the first week of November, BioAgilytix Labs, LLC, a portfolio company of Riverside Partners, purchased Cambridge Biomedical. Both Cambridge and BioAgilytix are contract research organizations (CROs) that develop novel therapeutic biologics and biosimilars, specializing in large molecule bioanalysis. The transaction expands BioAgilytix’s global footprint and adds further capacity by joining Cambridge Biomedical’s CLIA-certified, CAP-accredited, and GLP-compliant facility with its GxP laboratories in Durham, North Carolina and Hamburg, Germany. It also gives BioAgilytix a total of 400 employees. The merger follows a busy October for CROs, in which five deals were reported, accounting for... Read More »
Home Health & Hospice Deals Kick Off 2019

Home Health & Hospice Deals Kick Off 2019

The Home Health & Hospice sector is predicted to see a great deal more mergers and acquisitions in 2019 than it has in recent years. Bullish industry watchers cite the growing momentum behind value-based health care delivered in lower-cost settings as just one tailwind that is expected to boost the sector. This sector closed out 2018 with 82 deals in our database, the best year for M&A since 2014, when 81 deals were made public. Four deals are already on the books, all announced in the first week of the new year. Three are from private equity sponsors or their platform companies. One deal echoed a growing trend of joint ventures between not-for-profit health systems and for-profit... Read More »

CROs Are Back, Many with Specialties

We’ve documented the increase in biotechnology acquisitions and license deals by pharmaceutical companies in previous posts. But the impact of pharma’s move away from in-house R&D has benefited other sectors of the healthcare industry, particularly clinical research organizations (CROs). For those outside the technology side of healthcare, CROs provide outsourced research services to the pharmaceutical, biotechnology, and medical device industries on a contract basis. Through mid-November, we’ve seen an increase of 325% in deal volume for CROs, compared with the year before. In 2015, just five deals for these targets were announced. So far this year, 17 are on the... Read More »

March 2016’s Biggest Health Care Deals

Health care companies are still attracting buyers, and those in the services sectors seem to be the hottest. Last month saw healthy deal volume, at 134 transactions. For a year that started slowly for health care mergers and acquisitions, March 2016’s deal volume is only 3% lower than the same month a year ago. Industry sources have noted the dearth of deals across many industries going into March, even though some uncertainties that troubled markets earlier this year, such as China’s economic slow down, haven’t occupied center stage recently. Leverage is not an overwhelming concern, but credit has tightened over the past few months. And with the new, more onerous federal rules regarding... Read More »

Biotechnology CROs Are Trading Again

Two contract research organizations (CROs) have changed hands in the past two weeks. On March 17, Hamburg, Germany-based IPM Biotech was acquired by BioAgilytix, a portfolio company of Riverside Partners, in Durham, North Carolina. As its name implies, IPM Biotech specializes in biotech research, specifically in large molecule bioanalysis in the area of immunogenicity. The transaction expands BioAgilytix’s global footprint with IPM’s newly planned GLP and GMB laboratory facility. Its services complement IPM’s rich immunogenicity, pharmacokinetics and pharmacodynamics expertise. Less than a week later, LakePharma, Inc., a CRO in Belmont, California, acquired Blue Sky... Read More »